Axogen
AXGNNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $50.89 Prior regular-session close from the quote source.
- $50.62–$59.72 Regular-session low and high so far today.
- 4.4M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Jan 11 projected Projected for 2027-01-11 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $23.00–$59.72 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own AXGN if FDA-approved Avance, broader reimbursement, and focused hospital-account selling turn peripheral nerve repair into a larger repeat-use category.
AXGN price history
Loading recent earnings…
Investment thesis
What must happen next
FDA-approved Avance plus broader commercial and CMS reimbursement reduces hospital economic friction, so targeted trauma and academic accounts adopt Axogen’s nerve-repair algorithm more deeply across indications.StrengtheningMateriality: High
GAAP annual revenue increased 20.2% in FY2025 to $225.208 million, and MD&A says growth was driven by unit volume as well as price and product mix. If this holds, revenue growth is driven by real procedure adoption rather than one-time price or mix; if it breaks, the premium sales multiple has little support.
Watch: FDA confirmatory studies for Avance fail to verify clinical benefit or lead to restrictive labeling.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased 20.2% in FY2025 to $225.208 million, and MD&A says growth was driven by unit volume as.
Open source ↗Axogen’s full repair portfolio—graft, connector, protector, cap, and soft-tissue products—addresses more of the peripheral nerve repair workflow than a single conduit or autograft alternative, supporting premium procedure economics.StrengtheningMateriality: High
FY2025 GAAP gross margin was 74.3%, despite approximately $1.9 million of one-time Avance BLA approval costs, versus 75.8% in FY2024. If surgeons value the integrated portfolio, gross margin can remain attractive as volume scales; if alternatives become clinically equivalent, pricing and mix are vulnerable.
Watch: A large medtech competitor such as Integra LifeSciences produces conduit or scaffold data that matches Axogen outcomes in longer or mixed/motor nerve gaps at lower cost.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP gross margin was 74.3%, despite approximately $1.9 million of one-time Avance BLA approval costs, versus 75.8% in FY2024.
Open source ↗The high-potential-account strategy should eventually let Axogen grow faster than its sales, R&D, and administrative base, but only if deeper adoption inside Level 1 trauma and academic-affiliated hospitals raises revenue per trained account.HoldingMateriality: Medium
GAAP annual operating margin improved from approximately -21.4% in FY2022 to -1.8% in FY2024 before slipping to -3.5% in FY2025. This is the bridge from a promising product company to an investable earnings compounder; failure means growth remains expensive and dilutive.
Watch: The targeted-account model requires continual rep expansion, surgeon training, and case support such that sales and marketing stays structurally above 40% of revenue.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating margin improved from approximately -21.4% in FY2022 to -1.8% in FY2024 before slipping to -3.5% in FY2025.
Open source ↗The post-approval financing and loan repayment give Axogen enough runway to fund Avance launch execution without the balance sheet becoming the main constraint.StrengtheningMateriality: Medium
Cash was $35.548 million at December 31, 2025, up from $27.554 million at December 31, 2024. If runway is adequate, owners can focus on adoption and margins; if cash burn returns, dilution or financing risk can overwhelm business progress.
Watch: Avance launch inventory, manufacturing validation, or post-approval study costs consume cash faster than procedure adoption builds.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $35.548 million at December 31, 2025, up from $27.554 million at December 31, 2024.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
FDA-approved Avance plus broader commercial and CMS reimbursement reduces hospital economic friction, so targeted trauma and academic accounts adopt Axogen’s nerve-repair algorithm more deeply across indications. If this holds, revenue growth is driven by real procedure adoption rather than one-time price or mix; if it breaks, the premium sales multiple has little support.
Axogen’s full repair portfolio—graft, connector, protector, cap, and soft-tissue products—addresses more of the peripheral nerve repair workflow than a single conduit or autograft alternative, supporting premium procedure economics. If surgeons value the integrated portfolio, gross margin can remain attractive as volume scales; if alternatives become clinically equivalent, pricing and mix are vulnerable.
The high-potential-account strategy should eventually let Axogen grow faster than its sales, R&D, and administrative base, but only if deeper adoption inside Level 1 trauma and academic-affiliated hospitals raises revenue per trained account. This is the bridge from a promising product company to an investable earnings compounder; failure means growth remains expensive and dilutive.
The post-approval financing and loan repayment give Axogen enough runway to fund Avance launch execution without the balance sheet becoming the main constraint. If runway is adequate, owners can focus on adoption and margins; if cash burn returns, dilution or financing risk can overwhelm business progress.
All standing thesis claims
Original report summary
FDA-approved Avance, broader reimbursement, and focused hospital-account selling turn peripheral nerve repair into a larger repeat-use category.
Bull case and bear case
Bull case and bear case for Axogen
Where the evidence on Axogen stands: Holding on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 3 strengthening and 1 holding.
Bull case: what the evidence supports
FDA-approved Avance plus broader commercial and CMS reimbursement reduces hospital economic friction, so targeted trauma and academic accounts adopt Axogen’s nerve-repair algorithm more deeply across indications.
Axogen’s full repair portfolio—graft, connector, protector, cap, and soft-tissue products—addresses more of the peripheral nerve repair workflow than a single conduit or autograft alternative, supporting premium procedure economics.
The high-potential-account strategy should eventually let Axogen grow faster than its sales, R&D, and administrative base, but only if deeper adoption inside Level 1 trauma and academic-affiliated hospitals raises revenue per trained account.
The post-approval financing and loan repayment give Axogen enough runway to fund Avance launch execution without the balance sheet becoming the main constraint.
Bear case: what would count against it
FDA confirmatory studies for Avance fail to verify clinical benefit or lead to restrictive labeling.
A large medtech competitor such as Integra LifeSciences produces conduit or scaffold data that matches Axogen outcomes in longer or mixed/motor nerve gaps at lower cost.
The targeted-account model requires continual rep expansion, surgeon training, and case support such that sales and marketing stays structurally above 40% of revenue.
Thesis-Break Engine
Thesis-break watch · Axogen
No break has crossed Axogen’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedRegulation FD disclosure.
Axogen filed an SEC 8-K on 2026-10-01: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Axogen filed an SEC 8-K on 2026-09-10: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Axogen filed an SEC 8-K on 2026-07-29: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- FDA confirmatory studies for Avance fail to verify clinical benefit or lead to restrictive labeling.
- A large medtech competitor such as Integra LifeSciences produces conduit or scaffold data that matches Axogen outcomes in longer or mixed/motor nerve gaps at lower cost.
- The targeted-account model requires continual rep expansion, surgeon training, and case support such that sales and marketing stays structurally above 40% of revenue.
- Avance launch inventory, manufacturing validation, or post-approval study costs consume cash faster than procedure adoption builds.
AXGN news
Loading headlines…
Financial statements
AXGN income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
AXGN: quick answers
- When does Axogen (AXGN) report earnings next?
- Axogen's next results are projected for January 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on October 28, 2026. Earnings calendar
- What is AXGN's short interest?
- As of October 30, 2026, 7.0M AXGN shares were sold short, 11.7% of its shares outstanding, up 36.5% from the count before. At the stock's average daily volume that is 3.3 days to cover. FINRA publishes the count twice a month. AXGN short interest history
- Have members of Congress traded AXGN?
- 2 trades in AXGN have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed AXGN trade